Adverse effects of papillomavirus vaccines: pharmacovigilance data in 2008.
(1) Various groups have released reviews of the adverse effects reported with papillomavirus vaccines in 2008. The reports mainly involved local adverse effects, syncope and a few allergic reactions; (2) The frequency of these adverse effects seems low and similar to that observed with standard, well-known vaccines. No unexpected serious adverse effects occurred in 2008.
D000293:Adolescent; D052685:Alphapapillomavirus / Q000472:pathogenicity; D001315:Australia; D004342:Drug Hypersensitivity; D005060:Europe; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D017589:Immunization Programs; D007267:Injections / Q000009:adverse effects; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D013575:Syncope / Q000139:chemically induced; D014481:United States; D014581:Urticaria / Q000139:chemically induced; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18